A commercial stage biotechnology company developing a benchtop DNA printer, putting synthesis capabilities in the hands of end users.

The $9B market for custom DNAs, currently dominated by services model, relies on a chemical method that has reached the limits of its potential. Given the growth in gene editing, synthetic biology, genomics, and personalized medicine in the past decade, DNA synthesis technologies that can generate custom DNAs at speed and scale are needed to meet demand. DNA Script’s enzymatic DNA synthesis platform has surpassed legacy chemical methods in both capability and efficiency, and will become the new gold standard.  Their first commercial offering, the SYNTAX printer, offers the ability for DIY DNA synthesis that is fast, cheap, and easy to use. Expanded capabilities including RNA synthesis, automated gene assembly, and high throughput synthesis are on the horizon.